Bell Therapeutics Inc.

Bell Therapeutics Inc. specializes in the Sleep-Thera device, which is designed for sleep-related therapeutic applications. Based on the available information, this device likely addresses conditions such as sleep apnea or insomnia by providing targeted interventions. The company’s focus appears to be on Class I medical devices, which are generally considered low-risk and often include items like bandages, gloves, or non-invasive sleep therapy devices.

Bell Therapeutics Inc. is based in South Korea. While the company’s location influences its primary regulatory framework, its devices are also registered in the EU’s eudamed database, indicating compliance with European Union medical device regulations. This suggests the company may follow both Korean and EU regulatory standards depending on the market it serves, though individual devices must meet the specific requirements of each jurisdiction where they are authorized.

Bell Therapeutics Inc.’s devices are listed in the EU’s eudamed database, which is the official registry for medical devices authorized under EU regulations. Listing in eudamed ensures transparency and traceability for regulators, healthcare providers, and patients, confirming that the devices meet EU safety, performance, and compliance standards. This registry is particularly important for devices marketed within the European Economic Area, as it provides official documentation of their authorization status.

Bell Therapeutics Inc.’s devices fall under Class I classification, which is the lowest risk category for medical devices. Class I devices typically include items like bandages, examination gloves, or non-invasive sleep therapy devices like Sleep-Thera, where the risk to patients is minimal. This classification means the devices undergo less stringent regulatory scrutiny compared to higher-risk classes, but they still must comply with basic safety and performance requirements to ensure their intended use is met without undue risk.